Prevention of Cerebrovascular Disease in Patients with Myeloproliferatie Disorders View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-12

AUTHORS

M. M. Tanashyan, P. I. Kuznetsova, A. A. Shabalina, A. A. Raskurazhev

ABSTRACT

Introduction. Hemorheological abnormalities in patients with Ph-negative myeloproliferative disorders (MPD) may lead to the development and/or progression of cerebrovascular pathology. Adequate preventive therapy in such cases lowers the risk of cerebral thrombotic complications. Objective. Evaluation of the effect of dipyridamole and acetylsalicylic acid (ASA) on platelet and erythrocyte aggregation, as well as on morphofunctional properties of erythrocytes in patients with cerebrovascular disease (CVD) due to MPD. Materials and methods. The study comprised 40 patients with various forms of CVD and Рh-negative MPD: 20 patients received dipyridamole, and 20 received ASA for prevention of cerebral thrombotic complications. Mean patient’s age was 44.6 years [35; 58.5]. A thorough clinical and neurological examination was performed, as well as neuroimaging studies, coagulation tests, analysis of platelet aggregation and rheological properties of erythrocytes. Results. Within the observation period (median—6.3 months) no acute cerebrovascular events in both groups were registered. Platelet aggregation (induced by ADP or adrenaline) was similar in both groups. Dipyridamole and ASA were also similar in their effect on functional properties of erythrocytes. Conclusion. Our findings suggest that the therapeutic effect of dipyridamole concerning CVD is similar to that of ASA. Dipyridamole can be recommended for use in patients with Рh-negative MPD if other antiplatelet agents are contraindicated. More... »

PAGES

896-900

Identifiers

URI

http://scigraph.springernature.com/pub.10.1134/s0362119718080133

DOI

http://dx.doi.org/10.1134/s0362119718080133

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112768078


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Research Center of Neurology, Moscow, Russia", 
          "id": "http://www.grid.ac/institutes/grid.465332.5", 
          "name": [
            "Research Center of Neurology, Moscow, Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tanashyan", 
        "givenName": "M. M.", 
        "id": "sg:person.0577166305.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577166305.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Center of Neurology, Moscow, Russia", 
          "id": "http://www.grid.ac/institutes/grid.465332.5", 
          "name": [
            "Research Center of Neurology, Moscow, Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kuznetsova", 
        "givenName": "P. I.", 
        "id": "sg:person.014250177513.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014250177513.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Center of Neurology, Moscow, Russia", 
          "id": "http://www.grid.ac/institutes/grid.465332.5", 
          "name": [
            "Research Center of Neurology, Moscow, Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shabalina", 
        "givenName": "A. A.", 
        "id": "sg:person.013152200301.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013152200301.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Center of Neurology, Moscow, Russia", 
          "id": "http://www.grid.ac/institutes/grid.465332.5", 
          "name": [
            "Research Center of Neurology, Moscow, Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Raskurazhev", 
        "givenName": "A. A.", 
        "id": "sg:person.014646043437.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014646043437.60"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s13045-016-0242-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022295924", 
          "https://doi.org/10.1186/s13045-016-0242-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2404693", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022386089", 
          "https://doi.org/10.1038/sj.leu.2404693"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12", 
    "datePublishedReg": "2018-12-01", 
    "description": "Introduction. Hemorheological abnormalities in patients with Ph-negative myeloproliferative disorders (MPD) may lead to the development and/or progression of cerebrovascular pathology. Adequate preventive therapy in such cases lowers the risk of cerebral thrombotic complications. Objective. Evaluation of the effect of dipyridamole and acetylsalicylic acid (ASA) on platelet and erythrocyte aggregation, as well as on morphofunctional properties of erythrocytes in patients with cerebrovascular disease (CVD) due to MPD. Materials and methods. The study comprised 40 patients with various forms of CVD and \u0420h-negative MPD: 20 patients received dipyridamole, and 20 received ASA for prevention of cerebral thrombotic complications. Mean patient\u2019s age was 44.6 years [35; 58.5]. A thorough clinical and neurological examination was performed, as well as neuroimaging studies, coagulation tests, analysis of platelet aggregation and rheological properties of erythrocytes. Results. Within the observation period (median\u20146.3 months) no acute cerebrovascular events in both groups were registered. Platelet aggregation (induced by ADP or adrenaline) was similar in both groups. Dipyridamole and ASA were also similar in their effect on functional properties of erythrocytes. Conclusion. Our findings suggest that the therapeutic effect of dipyridamole concerning CVD is similar to that of ASA. Dipyridamole can be recommended for use in patients with \u0420h-negative MPD if other antiplatelet agents are contraindicated.", 
    "genre": "article", 
    "id": "sg:pub.10.1134/s0362119718080133", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1085127", 
        "issn": [
          "0362-1197", 
          "1608-3164"
        ], 
        "name": "Human Physiology", 
        "publisher": "Pleiades Publishing", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "44"
      }
    ], 
    "keywords": [
      "cerebrovascular disease", 
      "myeloproliferative disorders", 
      "negative myeloproliferative disorders", 
      "acetylsalicylic acid", 
      "thrombotic complications", 
      "platelet aggregation", 
      "acute cerebrovascular events", 
      "Ph-negative myeloproliferative disorders", 
      "effect of dipyridamole", 
      "cerebrovascular events", 
      "preventive therapy", 
      "neurological examination", 
      "antiplatelet agents", 
      "hemorheological abnormalities", 
      "cerebrovascular pathology", 
      "therapeutic effect", 
      "coagulation tests", 
      "patients", 
      "dipyridamole", 
      "observation period", 
      "complications", 
      "erythrocyte aggregation", 
      "disease", 
      "prevention", 
      "disorders", 
      "erythrocytes", 
      "such cases", 
      "group", 
      "therapy", 
      "morphofunctional properties", 
      "abnormalities", 
      "pathology", 
      "progression", 
      "age", 
      "platelets", 
      "risk", 
      "effect", 
      "study", 
      "examination", 
      "functional properties", 
      "years", 
      "findings", 
      "agents", 
      "period", 
      "cases", 
      "evaluation", 
      "aggregation", 
      "test", 
      "events", 
      "use", 
      "acid", 
      "development", 
      "analysis", 
      "form", 
      "method", 
      "materials", 
      "properties", 
      "rheological properties", 
      "Adequate preventive therapy", 
      "cerebral thrombotic complications", 
      "forms of CVD", 
      "Myeloproliferatie Disorders"
    ], 
    "name": "Prevention of Cerebrovascular Disease in Patients with Myeloproliferatie Disorders", 
    "pagination": "896-900", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112768078"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1134/s0362119718080133"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1134/s0362119718080133", 
      "https://app.dimensions.ai/details/publication/pub.1112768078"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:50", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_788.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1134/s0362119718080133"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1134/s0362119718080133'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1134/s0362119718080133'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1134/s0362119718080133'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1134/s0362119718080133'


 

This table displays all metadata directly associated to this object as RDF triples.

149 TRIPLES      22 PREDICATES      90 URIs      80 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1134/s0362119718080133 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N6f88d20751154ca2aedd52000e13cabc
4 schema:citation sg:pub.10.1038/sj.leu.2404693
5 sg:pub.10.1186/s13045-016-0242-9
6 schema:datePublished 2018-12
7 schema:datePublishedReg 2018-12-01
8 schema:description Introduction. Hemorheological abnormalities in patients with Ph-negative myeloproliferative disorders (MPD) may lead to the development and/or progression of cerebrovascular pathology. Adequate preventive therapy in such cases lowers the risk of cerebral thrombotic complications. Objective. Evaluation of the effect of dipyridamole and acetylsalicylic acid (ASA) on platelet and erythrocyte aggregation, as well as on morphofunctional properties of erythrocytes in patients with cerebrovascular disease (CVD) due to MPD. Materials and methods. The study comprised 40 patients with various forms of CVD and Рh-negative MPD: 20 patients received dipyridamole, and 20 received ASA for prevention of cerebral thrombotic complications. Mean patient’s age was 44.6 years [35; 58.5]. A thorough clinical and neurological examination was performed, as well as neuroimaging studies, coagulation tests, analysis of platelet aggregation and rheological properties of erythrocytes. Results. Within the observation period (median—6.3 months) no acute cerebrovascular events in both groups were registered. Platelet aggregation (induced by ADP or adrenaline) was similar in both groups. Dipyridamole and ASA were also similar in their effect on functional properties of erythrocytes. Conclusion. Our findings suggest that the therapeutic effect of dipyridamole concerning CVD is similar to that of ASA. Dipyridamole can be recommended for use in patients with Рh-negative MPD if other antiplatelet agents are contraindicated.
9 schema:genre article
10 schema:inLanguage en
11 schema:isAccessibleForFree false
12 schema:isPartOf N150a1fc292264e5a8c5869571ec3fc80
13 Nabf855dc1c5246eb8c87a983a192fae5
14 sg:journal.1085127
15 schema:keywords Adequate preventive therapy
16 Myeloproliferatie Disorders
17 Ph-negative myeloproliferative disorders
18 abnormalities
19 acetylsalicylic acid
20 acid
21 acute cerebrovascular events
22 age
23 agents
24 aggregation
25 analysis
26 antiplatelet agents
27 cases
28 cerebral thrombotic complications
29 cerebrovascular disease
30 cerebrovascular events
31 cerebrovascular pathology
32 coagulation tests
33 complications
34 development
35 dipyridamole
36 disease
37 disorders
38 effect
39 effect of dipyridamole
40 erythrocyte aggregation
41 erythrocytes
42 evaluation
43 events
44 examination
45 findings
46 form
47 forms of CVD
48 functional properties
49 group
50 hemorheological abnormalities
51 materials
52 method
53 morphofunctional properties
54 myeloproliferative disorders
55 negative myeloproliferative disorders
56 neurological examination
57 observation period
58 pathology
59 patients
60 period
61 platelet aggregation
62 platelets
63 prevention
64 preventive therapy
65 progression
66 properties
67 rheological properties
68 risk
69 study
70 such cases
71 test
72 therapeutic effect
73 therapy
74 thrombotic complications
75 use
76 years
77 schema:name Prevention of Cerebrovascular Disease in Patients with Myeloproliferatie Disorders
78 schema:pagination 896-900
79 schema:productId N10ddfbda701d42b597ef90e6e8e60b13
80 N1cf8f5f155f54103b9a977bc0244c77b
81 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112768078
82 https://doi.org/10.1134/s0362119718080133
83 schema:sdDatePublished 2022-01-01T18:50
84 schema:sdLicense https://scigraph.springernature.com/explorer/license/
85 schema:sdPublisher N23520511050c4dd4bb0729a3ef6fa187
86 schema:url https://doi.org/10.1134/s0362119718080133
87 sgo:license sg:explorer/license/
88 sgo:sdDataset articles
89 rdf:type schema:ScholarlyArticle
90 N0ac34bfdc61a444497a6e9ca4ba48a45 rdf:first sg:person.014250177513.74
91 rdf:rest N9e92912bae0648fd945957f44059e55b
92 N10ddfbda701d42b597ef90e6e8e60b13 schema:name dimensions_id
93 schema:value pub.1112768078
94 rdf:type schema:PropertyValue
95 N150a1fc292264e5a8c5869571ec3fc80 schema:issueNumber 8
96 rdf:type schema:PublicationIssue
97 N1cf8f5f155f54103b9a977bc0244c77b schema:name doi
98 schema:value 10.1134/s0362119718080133
99 rdf:type schema:PropertyValue
100 N23520511050c4dd4bb0729a3ef6fa187 schema:name Springer Nature - SN SciGraph project
101 rdf:type schema:Organization
102 N4cda3e1bc0a240a08cb3ac6b803241c7 rdf:first sg:person.014646043437.60
103 rdf:rest rdf:nil
104 N6f88d20751154ca2aedd52000e13cabc rdf:first sg:person.0577166305.86
105 rdf:rest N0ac34bfdc61a444497a6e9ca4ba48a45
106 N9e92912bae0648fd945957f44059e55b rdf:first sg:person.013152200301.49
107 rdf:rest N4cda3e1bc0a240a08cb3ac6b803241c7
108 Nabf855dc1c5246eb8c87a983a192fae5 schema:volumeNumber 44
109 rdf:type schema:PublicationVolume
110 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
111 schema:name Medical and Health Sciences
112 rdf:type schema:DefinedTerm
113 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
114 schema:name Clinical Sciences
115 rdf:type schema:DefinedTerm
116 sg:journal.1085127 schema:issn 0362-1197
117 1608-3164
118 schema:name Human Physiology
119 schema:publisher Pleiades Publishing
120 rdf:type schema:Periodical
121 sg:person.013152200301.49 schema:affiliation grid-institutes:grid.465332.5
122 schema:familyName Shabalina
123 schema:givenName A. A.
124 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013152200301.49
125 rdf:type schema:Person
126 sg:person.014250177513.74 schema:affiliation grid-institutes:grid.465332.5
127 schema:familyName Kuznetsova
128 schema:givenName P. I.
129 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014250177513.74
130 rdf:type schema:Person
131 sg:person.014646043437.60 schema:affiliation grid-institutes:grid.465332.5
132 schema:familyName Raskurazhev
133 schema:givenName A. A.
134 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014646043437.60
135 rdf:type schema:Person
136 sg:person.0577166305.86 schema:affiliation grid-institutes:grid.465332.5
137 schema:familyName Tanashyan
138 schema:givenName M. M.
139 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577166305.86
140 rdf:type schema:Person
141 sg:pub.10.1038/sj.leu.2404693 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022386089
142 https://doi.org/10.1038/sj.leu.2404693
143 rdf:type schema:CreativeWork
144 sg:pub.10.1186/s13045-016-0242-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022295924
145 https://doi.org/10.1186/s13045-016-0242-9
146 rdf:type schema:CreativeWork
147 grid-institutes:grid.465332.5 schema:alternateName Research Center of Neurology, Moscow, Russia
148 schema:name Research Center of Neurology, Moscow, Russia
149 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...